Dec. 2 at 2:13 AM
$NPHC
For three long years we’ve weathered silence, delays, and a dormant ticker—yet we’ve remained. That patience is finally beginning to show signs of payoff. Nutra Pharma has been steadily filing its delinquent financials, 2024 reports are underway, and with 2025 filings next, the company is inching closer to becoming fully current.
This is the closest we’ve been in years to seeing NPHC reawaken. Long-term holders have shown extraordinary resilience when most would have walked away. That persistence deserves recognition—and it deserves results.
The finish line is in sight. Shareholders have upheld their end of the journey with patience and belief. Now it’s time for the company to match that commitment with urgency. Completing the remaining filings accurately and expeditiously is not just an administrative step—it is a promise kept, a restoration of credibility, and the key to unlocking real value for everyone involved.
Momentum is building. Eyes are watching.
Let’s see this finish!